Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kezar Life Sciences
Biotech
Kezar drops solid tumor yet to prove its worth in phase 1 trial
Kezar Life Sciences is dropping its unpromising phase 1 solid tumor drug as the biotech goes all-in on its lead autoimmune hepatitis program.
James Waldron
Aug 14, 2024 5:09am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
Kezar offloads 41% of staff, CEO to keep lupus candidate affloat
Oct 4, 2023 7:40am
Inventiva, Kezar sell Asian rights to NASH and autoimmune assets
Sep 21, 2023 9:00am
Agios replaces CEO after recent FDA nod—Chutes & Ladders
Jul 15, 2022 9:30am
Kezar's lupus data spur hope for inflammatory drug
Jun 28, 2022 8:50am